1 Wall Street Analyst Thinks Pfizer Stock Is Going to $45. Is It a Buy Around $26?
Pfizer's stock is still reeling from the decline of its coronavirus-related sales. At least one Wall Street analyst thinks that it has a bright future.
Trade Tracker: Josh Brown buys more Pfizer
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's 'Halftime Report' to explain why he believes Pfizer is one of the best opportunities in the market right now.
Pfizer Inc. (PFE) TD Cowen 44th Annual Health Care Conference
Pfizer Inc. (NYSE:PFE ) TD Cowen 44th Annual Health Care Conference March 4, 2024 11:10 AM ET Company Participants David Denton - Chief Financial Officer and Executive Vice President Conference Cal...
6%-Yielding Pfizer Is An Ultra-Deep-Value Gem In An Expensive Market
The market valuation has become lofty, boosted by 2021-like buying behavior and a surge in growth/tech stocks. In this environment, value stocks have become very attractive, potentially allowing in...
1 S&P 500 Dividend Stock Down 56% to Buy and Hold Forever
This stock has plunged in recent years mainly because of declining demand for two of its key products. However, it's poised to return to growth, is dirt cheap, and pays an especially juicy dividend.
1 Magnificent S&P 500 Dividend Stock Down 56% to Buy and Hold Forever
The fading interest in combating COVID-19 has taken a toll on Pfizer's top and bottom lines. Pfizer stock has risen and fallen with its coronavirus business, but the pullback has been exaggerated.
Pfizer says its RSV shot is protective through a second year
Pfizer on Thursday said a single dose of its new respiratory syncytial virus (RSV) vaccine Abrysvo maintained its ability to protect against the illness through a second year of respiratory disease...
Pfizer Stock Has 30% Upside, According to 1 Wall Street Analyst
Pfizer's dividend yield is 50% higher than its historical average right now. Pfizer's latest acquisition could lead to a resurgence in growth -- but it doesn't have to.
Pfizer: Finally, A Dividend Stock Worth Buying
Dividend stocks have been overvalued due to the influx of retirees seeking income, but Pfizer is an exception. Pfizer is trading at a good valuation and offers a decent yield with potential for gro...
Pfizer Stock Has 29% Upside, Says a New Bull
Guggenheim analysts initiated coverage of drug firm Pfizer at Buy with a $36 price target. Shares have lagged behind the market in recent years.
Pfizer's expectations have been rightsized, has potential for $5 EPS: Cantor Fitzgerald's Chen
Louise Chen, Cantor Fitzgerald, and Michael Yee, Jefferies, joins 'Power Lunch' to discuss Chen's bull case for Pfizer, Yee's bull case for Moderna, and more.
Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod
The approval for Pfizer's (PFE) Velsipity (etrasimod) is based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12.
Pfizer inflammatory bowel disease drug wins European Commission approval
Pfizer on Monday said the European Commission has approved the company's drug to treat patients with an inflammatory bowel disease called ulcerative colitis.
Pfizer at 10-year support: Is it a massive buy opportunity?
For shareholders of the multinational biotech giant Pfizer Inc. NYSE: PFE, it might feel like the stock's all-time highs set during the pandemic were centuries ago. After making its COVID-19-relate...
Pfizer agrees to pay $93 mln to settle Lipitor antitrust lawsuit
Pfizer has agreed to pay $93 million to settle antitrust claims by wholesale drug distributors that accused it of conspiring with India's Ranbaxy Laboratories to delay sales of less expensive, gene...
Related Companies